

## Limited Submission Funding Opportunities – updated 11/29/19

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of \$50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu)

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

### Process

Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu). In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:

1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at [ecor@mgh.harvard.edu](mailto:ecor@mgh.harvard.edu).

### CURRENT OPPORTUNITIES

#### 1. Advances in Integrating Genetics into Clinical Care (HRSA)

<https://www.hrsa.gov/grants/fundingopportunities/default.aspx?id=c6dabedd-c539-48bd-9940-7c30188aa0a1>

**MGH LOI Deadline: 11/29/19**

Sponsor Deadline: 1/14/20

This notice announces the opportunity to apply for funding under the Advances in Integrating Genetics into Clinical Care (AIGCC) program. The purpose of this program is to serve as a national resource on the use of genetic and genomic information in clinical practice for genetic service providers, primary and specialty health care providers, and families. The program will accomplish this by implementing the priorities below.

## Limited Submission Funding Opportunities – updated 11/29/19

### 2. Assessing the Burden of Diabetes by Type in Children, Adolescents, and Young Adults (DiCAYA) (CDC Grant)

<https://www.grants.gov/web/grants/view-opportunity.html?oppld=320257>

**MGH LOI Deadline: 12/02/19**

Sponsor LOI Deadline: 12/09/19

Sponsor Deadline: 1/09/20

The purpose of this NOFO is to assess the incidence and prevalence of diabetes among children, adolescents and young adults in the United States and provide estimates by diabetes type, age, sex, race/ethnicity and geographic area. Component A focuses on surveillance of incidence and prevalence of diabetes among children and adolescents (< 18 years). Component B focuses on surveillance of incidence and prevalence of diabetes among young adults (18 to < 45 years). Component C serves as a Coordinating Center to provide an infrastructure for standardized approaches, analytical methods, and surveillance measures. It also serves as a repository for the Component A and B data and provides consolidated estimates by diabetes type, age, race/ethnicity and geographic area.

**Please note:** In your MGH letter of intent, please indicate the component that you will be applying for.

### 3. Stimulating Access to Research in Residency (StARR) (R38)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-023.html>

**MGH LOI Deadline: 12/03/19**

NIH Deadline: 2/13/20

The purpose of this program is to recruit and retain outstanding, postdoctoral-level health professionals who have demonstrated potential and interest in pursuing careers as clinician-investigators. To address the growing need for this critical component of the research workforce, this funding opportunity seeks applications from institutional programs that can provide outstanding mentored research opportunities for Resident-Investigators and foster their ability to transition to individual career development research awards. The program will support institutions to provide support for up to 2 years of research conducted by Resident-Investigators in structured programs for clinician-investigators with defined program milestones.

### 4. Medical Scientist Training Program (T32)

<https://grants.nih.gov/grants/guide/pa-files/PA-19-036.html>

**MGH LOI Deadline: 12/04/19**

NIH Deadline: 1/25/20

The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained physician-scientist leaders available to meet the Nation's biomedical research needs. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-based approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., M.D., D.O., D.V.M., D.D.S., and research doctorate degrees (Ph.D. or equivalent). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the physician-scientist workforce. NIGMS expects that

## Limited Submission Funding Opportunities – updated 11/29/19

the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

This FOA does not allow appointed trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

### 5. Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers (P30 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/pa-files/PA-20-043.html>

**MGH LOI Deadline: 12/11/19**

NIH Deadline: 1/25/20

This Funding Opportunity Announcement (FOA) invites applications for P30 Cancer Center Support Grants (CCSGs) to support NCI-designated Cancer Centers. CCSGs support three types of Cancer Centers: 1) Comprehensive Cancer Centers, which demonstrate reasonable depth and breadth of research activities in each of three major areas: basic laboratory; clinical; and prevention, control and population-based research, and which have substantial transdisciplinary research that bridges these scientific areas; and 2) Clinical Cancer Centers, which are primarily focused on basic laboratory; clinical; and prevention, cancer control, and population-based research; or some combination of these areas, and 3) Basic Cancer Centers, which focus on basic laboratory research. The purpose of all types of NCI-designated Cancer Centers is to capitalize on all institutional cancer research capabilities, integrating meritorious research into a single transdisciplinary research enterprise across all institutional boundaries. Cancer Centers supported through this FOA are expected to serve as major sources of discovery of the nature of cancer and of development of more effective approaches to prevention, diagnosis, and therapy; to contribute significantly to the development of Shared Resources that support research; to collaborate and coordinate their research efforts with other NCI-funded programs and investigators; and to disseminate research findings for the benefit of the community.

### 6. Outstanding New Environmental Scientist (ONES) Award (R01 Clinical Trial Optional)

<https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-18-001.html>

**MGH LOI Deadline: 12/30/19**

NIH LOI Deadline: 1/28/20

NIH Deadline: 2/28/20

The Outstanding New Environmental Scientist (ONES) Award is intended to identify the most talented Early Stage Investigators (ESIs) who intend to make a long-term commitment to research in the Environmental Health Sciences and assist them in launching an innovative research program focused on the understanding of environmental exposure effects on people's health.

## Limited Submission Funding Opportunities – updated 11/29/19

### 7. St. Baldrick's Foundation

<https://www.stbaldricks.org/for-researchers>

**MGH LOI Deadline: 1/3/20**

Foundation LOI Deadline: 1/31/20

Application Deadline: 3/27/20

The St. Baldrick's Foundation is proud to fund lifesaving research throughout the world, awarding grants that focus on all major types of childhood cancers.

St. Baldrick's donors and volunteers have enabled the foundation to fund over \$200 million in grants, allowing the foundation to fund more in childhood cancer research grants than any organization except the U.S. government. Every grant goes through a rigorous scientific review process, ensuring every dollar has the greatest possible impact for children with cancer. Funding Priorities include new discovery research, translational research and early phase clinical trials, phase 3 clinical trials and infrastructure support, and education of new pediatric oncology researchers.

MGH may submit one LOI/application in all other St. Baldrick's funding categories, and two LOI/applications in the Research Grant Award category. In the internal LOI, please indicate what category you will be submitting under. Click [here](#) for information on the spring cycle of funding.

### 8. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-014.html>

**MGH LOI Deadline: 1/10/20**

NIH LOI Deadline: 1/26/20

NIH Application Deadline: 2/26/20

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. Each eligible institution (defined as having a unique DUNS number or NIH IPF number) may submit a combined total of three applications to RFA-CA-20-014 and/or RFA-CA-20-015. Additionally, each application must be in a different scientific area (Data Science, Cancer Control Science, Other Sciences).

*This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (RFA-CA-20-015).*

## Limited Submission Funding Opportunities – updated 11/29/19

### 9. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required) – NEW!

<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-015.html>

**MGH LOI Deadline: 1/10/20**

NIH LOI Deadline: 1/26/20

NIH Application Deadline: 2/26/20

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research training beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply. Each eligible institution (defined as having a unique DUNS number or NIH IPF number) may submit a combined total of three applications to RFA-CA-20-014 and/or RFA-CA-20-015. Additionally, each application must be in a different scientific area (Data Science, Cancer Control Science, Other Sciences).

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-CA-20-014).